Monitor upcoming Phase 1/2 data readouts in 1H26, particularly from RESET-SLE and RESET-SSc, which could inform registrational pathways and potentially catalyze investor interest despite lack of near-term revenue.
Price Chart
Executive Summary
Cabaletta Bio reported Q4 and full-year 2025 financial results, highlighted by increased R&D spending and a cash position of $133.6 million, sufficient to fund operations into Q4 2026. The company reiterated key clinical milestones for rese-cel, including complete Phase 1/2 data readouts in 1H26 and a planned BLA submission for myositis in 2027.
Key Financial Metrics
Key Facts
- R&D expenses increased to $36.2M (Q4 2025) from $25.5M (Q4 2024); full-year R&D rose to $142.7M from $97.2M.
- G&A expenses decreased to $6.4M (Q4 2025) from $8.3M (Q4 2024).
- Cash, cash equivalents, and short-term investments totaled $133.6M as of December 31, 2025, down from $164.0M a year prior.
- Company raised an additional $30.0M in Q1 2026 via ATM sales and warrant exercises.
- Cash runway expected through Q4 2026.
- Complete Phase 1/2 data from RESET-SLE, RESET-SSc, and RESET-MG trials expected in 1H26.
- BLA submission for rese-cel in myositis anticipated in 2027 based on 17-patient registrational cohort.
Financial Impact
Increased R&D spend by $45.5M year-over-year; net loss widened to $167.9M in 2025 from $115.9M in 2024.
Risk Factors
- High cash burn with no approved products; dependent on successful clinical outcomes and future financing.
- Clinical timelines are forward-looking and subject to delays; no guarantee that data will support BLA submission or approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260280 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $2.91 $2.46 | ▼ −15.46% | ▼ −15.57% | $1.91 (−34.36%) |
Aug 15, 2026 6w ago | Institutional Cluster | $2.89 $3.10 | ▲ +7.27% | ▲ +8.46% | $1.91 (−33.91%) |
Aug 13, 2026 7w ago | 8-K | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Aug 13, 2026 7w ago | Press Release | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.01 $2.84 | ▼ −5.65% | ▼ −6.32% | $1.91 (−36.54%) |
Jun 3, 2026 17w ago | 8-K | $3.58 $3.04 | ▼ −15.08% | ▼ −11.26% | $1.91 (−46.65%) |
Jun 1, 2026 17w ago | DEFA14A | $3.67 $3.25 | ▼ −11.44% | ▼ −8.69% | $1.91 (−47.96%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▼ −2.22% | ▼ −2.93% | $1.91 (+47.09%) |
May 14, 2026 20w ago | Press Release | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access